Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Karolin Hubert"'
Autor:
Mathias Hänel, Regina Herbst, Maxi Wass, Herbert G. Sayer, Song-Yau Wang, Georg Maschmeyer, Karolin Hubert, Haifa Kathrin Al-Ali, Nadia Jaekel, Dietger Niederwieser, Oana Brosteanu, Christoph Kahl, Susann Schulze
Publikováno v:
Blood. 132:83-83
The heterogeneity of AML requires a personalized treatment strategy to achieve a high initial response and translate this response into long-term survival. Based on a possible synergistic effect of azacitidine (AZA) and cytarabine (ARA-C) when AZA is
Autor:
Oliver Leismann, Gesine Bug, U. Platzbecker, Haifa Kathrin Al-Ali, K Lieder, Sandro Altamura, Stefan Albrecht, K de Haas, Dietger Niederwieser, Nadja Jaekel, Karolin Hubert, N Kröger, Michael Stadler, Martina U. Muckenthaler
Publikováno v:
Bone marrow transplantation. 51(1)
Elevated serum ferritin contributes to treatment-related morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). The multicenter DE02 trial assessed the safety, efficacy and impact of deferasirox on iron homeostasis a
Autor:
Anne Koehler, Prashanth Gopalakrishna, Dietger Niederwieser, Astrid Monecke, Karolin Hubert, Udo Siebolts, Haifa Kathrin Al-Ali, Claudia Wickenhauser, Thoralf Lange
Publikováno v:
Annals of Hematology. 94:1929-1930
Autor:
Nadja Jaekel, Rayk Stengel, Martin Roskos, Rainer Krahl, Song-Yau Wang, Melanie Schneider, Susann Schulze, Haifa Kathrin Al-Ali, Karolin Hubert, Dietger Niederwieser
Publikováno v:
Blood. 126:2014-2014
Allogeneic HCT is curative in myelofibrosis (MF) with a survival (OS) advantage compared to non-JAK-inhibitor treatments in patients (pts) with Int-2/high-risk DIPSS (Kroeger et al, Blood 2015). On the other hand, data demonstrate a OS benefit of the
Autor:
Mathias Haenel, Song-Yau Wang, Susann Schultze, Nadja Jaekel, Christian Jakob, Regina Herbst, Georg Maschmeyer, Dietger Niederwieser, Oana Brosteanu, Haifa Kathrin Al-Ali, Rainer Krahl, Karolin Hubert
Publikováno v:
Blood. 126:1346-1346
The prognosis of AML in patients (pts) >60 years (y) is poor and there is no universally accepted standard approach. After induction chemotherapy (IC), a complete remission (CR+CRi) rate of 56.4% and a mortality of 21% at day (d) 90 are expected (Nie
Autor:
Udo Siebolts, Astrid Monecke, Thoralf Lange, Dietger Niederwieser, Gopalakrishna Prashanth, Karolin Hubert, Claudia Wichenhauser, Haifa Kathrin Al-Ali
Publikováno v:
Blood. 124:1836-1836
The JAK1/2 inhibitor ruxolitinib (RUX) is effective in decreasing symptomatic splenomegaly, and constitutional symptoms in patients with myelofibrosis (MF). Long-term data suggest that treatment with RUX is associated with a survival benefit, and may
Autor:
Thoralf Lange, Kathrin Wildenberger, Rayak Stengel, Dietger Niederwieser, Schwabe Scarlett, Karolin Hubert, Anne Koehler, Martin Roskos, Rainer Krahl, Song-Yau Wang, Elisabeth Koehler, Melanie Schneider, Haifa Kathrin Al-Ali, Ines Kovacs, Nadja Jaekel, Karoline Schubert
Publikováno v:
Blood. 124:1860-1860
In retrospective studies, CALR mutation is found to be a favorable prognostic variable in myelofibrosis (MF) compared with JAK2, or MPL mutations. With the availability of the JAK1/JAK2 inhibitor ruxolitinib (RUX) for treatment of MF, it is not yet k
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Karolin Hubert, Nicolaus Kroeger, Kai Lieder, Haifa Kathrin Al-Ali, Uwe Platzbecker, Gesine Bug, Michael Stadler, Stefan Albrecht, Oliver Leismann, Dietger Niederwieser, Katherina de Haas, Nadja Jaekel
Publikováno v:
Blood. 120:485-485
Abstract 485 Transfusional iron overload (TIO) contributes considerably to treatment-related morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). Data on post-HCT treatment of secondary hemochromatosis are limited. The r